Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 86 P105 | DOI: 10.1530/endoabs.86.P105

SFEBES2022 Poster Presentations Neuroendocrinology and Pituitary (72 abstracts)

Case Series: Primary / neo-adjuvant 131I-MIBG therapy as a safe and effect treatment in the management of pheochromocytoma / paraganglioma

Michael Onyema , James Crane , Saira Reynolds & Benjamin Whitelaw

King’s College Hospital, London, United Kingdom

Background: As per 2014 Endocrine Society guidelines, 131I-MIBG therapy is usually reserved for metastatic or unresectable disease in patients with pheochromocytoma / paraganglioma. In this series, we describe three patients effectively treated with primary 131I-MIBG therapy. The indications were primary neo-adjuvant therapy prior to surgery, or palliative.

Case series: Case 1 – 18-year-old male with a 60 mm para-aortic paraganglioma on CT scan after a presentation with trauma. Urinary catecholamines were elevated and alpha blockade commenced. Surgical intervention was deemed of unacceptably high risk due to proximity to major mesenteric vessels. One cycle of primary 131I-MIBG therapy was administered. The lesion reduced to 53 mm on repeat imaging, now clear of vessels and amenable to resection. No complications were encountered. Case 2 – 31-year-old female with SDHB mutation, diagnosed with a 56 mm pelvic paraganglioma after presentation with a crisis. Plasma metanephrines were elevated and alpha blockade commenced. Due to a COVID-19 related surgical delay, she received a single cycle of primary 131I-MIBG therapy prior to resection, which was well tolerated. No repeat imaging was performed but the surgical specimen appeared similar in diameter to radiological measurements. Case 3 – 79-year-old female diagnosed with a 150 mm mesenteric paraganglioma after presenting with urinary discomfort. Plasma metanephrines were normal and surgery was considered too high risk due to proximity to mesenteric vessels. The lesion reduced to 120 mm after three cycles of 131I-MIBG therapy. After multidisciplinary team review, surgery was considered feasible, but conservative management was pursued due to comorbidities.

Discussion: In the cases described primary131I-MIBG therapy was well tolerated without significant side effects or precipitation of pheochromocytoma crisis. In two cases significant reduction of tumour volume was achieved. These outcomes suggest primary 131I-MIBG therapy may be a safe and effective treatment approach pre-surgery (neo-adjuvant) or for palliation without the presence of metastasis.

Volume 86

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.